News & Events
News & Events
[Kiho Ilbo] Bio-venture company Qurient goes public on KOSDAQ
2016-03-02
Qurient Co. Ltd., a spin-off of Institut Pasteur Korea (IPK), was listed on KOSDAQ on Feb. 29, 2016. Qurient is the first biotech company listed on KOSDAQ through the open innovation and project management system. In 2008, IPK invested in developing Qurient which transitions validated targets to drug candidates. Qurient has Q203, a drug-resistant tuberculosis candidate licensed from IPK, that has been approved for clinical trial phase 1 by the FDA. Also Q301, a drug candidate for atopic dermatitis that is in clinical trial phase 2 by the FDA and Q701, a drug candidate for anticancer immunity/resistant cancer that is currently on non-clinical trial.
Source: Kiho Ilbo (March 1, 2016)